Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
Status:
Active, not recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This is a phase II open-label study evaluating the efficacy and safety of nab-paclitaxel
cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.